Abstract
Objectives To evaluate the National Early Warning Score (NEWS2), currently recommended in the UK for risk-stratification of severe COVID-19 outcomes, and subsequently identify and validate a minimal set of common parameters taken at hospital admission that improve the score.
Design Retrospective observational cohort with internal and multi-hospital external validation.
Setting Secondary care.
Interventions Not applicable.
Participants Main outcome measures
Results Training and temporal external validation cohorts comprised 1464 patients admitted to King’s College Hospital NHS Foundation Trust (KCH) with COVID-19 disease from 1st March to 30th April 2020. External validation cohorts included 3869 patients from two UK NHS Trusts (Guys and St Thomas’ Hospitals, GSTT and University Hospitals Southampton, UHS) and two hospitals in Wuhan, China (Wuhan Sixth Hospital and Taikang Tongji Hospital).
The primary outcome was patient status at 14 days after symptom onset categorised as severe disease (transferred to intensive care unit or death). Age, physiological measures, blood biomarkers, sex, ethnicity and comorbidities (hypertension, diabetes, cardiovascular, respiratory and kidney diseases) were included.
Conclusions NEWS2 score on admission was a weak predictor of severe COVID-19 infection (AUC = 0.628). Adding age and common blood tests (CRP, neutrophil count, estimated GFR and albumin) provided substantial improvements to a risk stratification model, particularly in relation to sensitivity, but performance was only moderate (AUC = 0.753). Improvement over NEWS2 remained robust and generalisable in GSTT (AUC = 0.817), UHS (AUC = 0.835) and Wuhan hospitals (AUC = 0.918).
Adding age and a minimal set of blood parameters to NEWS2 improves the detection of patients likely to develop severe COVID-19 outcomes. This finding was replicated across NHS and non-UK hospitals. Adding a few common parameters to a pre-existing acuity score allows rapid and easy implementation of this risk-scoring system.
Key Messages
The National Early Warning Score (NEWS2), currently recommended for severe COVID-19 disease in the UK shows overall poor discrimination for severe outcomes (transfer to ICU or death). It can be improved by the addition of a small number of blood and physiological parameters routinely measured at hospital admission.
The addition of age and a minimal set of common blood tests (C-reactive protein, neutrophil count, estimated GFR and albumin) provided substantial improvements in a risk stratification model.
Although predictive performance varied from hospital to hospital, the improvement over NEWS2 alone was consistent across different patient cohorts.
The proposed addition of a limited number of dichotomised parameters is easily derived from a pre-existing acuity score would be substantially easier to implement in a short-time scale compared to novel high-dimensional risk-scoring systems.
Competing Interest Statement
JTHT received research support and funding from InnovateUK, Bristol-Myers-Squibb, iRhythm Technologies, and holds shares <5,000 pounds in Glaxo Smithkline and Biogen.
Funding Statement
DMB is funded by a UKRI Innovation Fellowship as part of Health Data Research UK MR/S00310X/1 (https://www.hdruk.ac.uk). RB is funded in part by grant MR/R016372/1 for the King’s College London MRC Skills Development Fellowship programme funded by the UK Medical Research Council (MRC, https://mrc.ukri.org) and by grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR, https://www.nihr.ac.uk) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. RJBD is supported by: (1) NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, London, U.K. (2) Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. (3) The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; it is chaired by DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC. (4) The National Institute for Health Research University College London Hospitals Biomedical Research Centre. (5) National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. (5) The UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare (6) the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust. KO’G is supported by an MRC Clinical Training Fellowship (MR/R017751/1). WW is supported by a Health Foundation grant. AD and VC acknowledge support from National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) South London at King’s College Hospital NHS Foundation Trust and the Royal College of Physicians, as well as the support from the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. VC is additionally supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. RZ is supported by a King’s Prize Fellowship. AS is supported by a King’s Medical Research Trust studentship. JTHT is supported by London AI Medical Imaging Centre for Value-Based Healthcare (AI4VBH) and the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust. FB and PTTH are funded by National Institute for Health Research (NIHR) Biomedical Research Centre, Data Sciences at University Hospital Southampton NHS Foundation Trust and the Clinical Informatics Research Unit, University of Southampton. JB is funded by the Clinical Informatics Research Unit, University of Southampton, and part funded by the Global Alliance for Chronic Disease (GDAC). AP is part funded by UHS Digital, University Hospital Southampton, Tremona Road, Southampton. AJS is supported by a Digital Health Fellowship through Health Education England (Wessex). HW and HZ are supported by Medical Research Council and Health Data Research UK Grant (MR/S004149/1), Industrial Strategy Challenge Grant (MC_PC_18029) and Wellcome Institutional Translation Partnership Award (PIII054). XW is supported by National Natural Science Foundation of China (grant number 81700006). AMS is supported by the British Heart Foundation (CH/1999001/11735), the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London (IS-BRC-1215-20006), and the Fondation Leducq. AP is partially supported by NIHR NF-SI-0617-10120. This work was supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC) Clinical and Research Informatics Unit (CRIU), NIHR Health Informatics Collaborative (HIC), and by awards establishing the Institute of Health Informatics at University College London (UCL). This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centres at South London and Maudsley NHS Foundation Trust, London AI Medical Imaging Centre for Value-Based Healthcare, and Guy’s & St Thomas’ NHS Foundation Trust, both with King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would also like to thank all the clinicians managing the patients, the patient experts of the KERRI committee, Professor Irene Higginson, Professor Alastair Baker, Professor Jules Wendon, Dan Persson and Damian Lewsley for their support. The authors acknowledge use of the research computing facility at King’s College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy’s & St. Thomas’ NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy’s & St. Thomas’ Charity (TR130505). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, King’s College London, or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project operated under London South East Research Ethics Committee approval (reference 18/LO/2048) granted to the King’s Electronic Records Research Interface (KERRI). Given the current context, specific work on COVID19 research was reviewed with a virtually convened 4-expert patient panel input on a virtual committee with Caldicott Guardian oversight. In addition, the KERRI database used in this study was developed according to KCH use of data for research guidelines (https://www.kch.nhs.uk/research/use-of-data-for-research) and patient engagement groups for this dataset have been conducted in 2018-2019.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code and pre-trained models are available at https://github.com/ewancarr/NEWS2-COVID-19 and openly shared for testing in other COVID datasets. Source text from patient records used at all sites in the study will not be available due to inability to safely fully anonymise up to the Information Commissioner Office (ICO) standards and would be likely to contain strong identifiers (e.g. names, postcodes) and highly sensitive data (e.g. diagnoses). A subset of the KCH dataset limited to anonymisable information (e.g. only SNOMED codes and aggregated demographics) is available on request to researchers with suitable training in information governance and human confidentiality protocols subject to approval by the King’s College Hospital Information Governance committee; applications for research access should be sent to kch-tr.cogstackrequests@nhs.net. This dataset cannot be released publicly due to the risk of re-identification of such granular individual level data, as determined by the King’s College Hospital Caldicott Guardian. The GSTT dataset cannot be released publicly due to the risk of re-identification of such granular individual level data, as determined by the Guy’s and St. Thomas’s Trust Caldicott Guardian. The UHS dataset cannot be released publicly due to the risk of re-identification of such granular individual level data, as determined by the University Hospital Southampton Caldicott Guardian. The Wuhan dataset used in the study will not be available due to inability to fully anonymise in line with ethical requirements. Applications for research access should be sent to TS and details will be made available via https://covid.datahelps.life/prediction/.
